Advancing Asthma Management: Economic Burden, Unmet Needs, and the Evolving Role of IL-5 Inhibition

EP. 1: Type 2 Inflammation and the Economic Cost of Severe Asthma

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 6th 2026

Most patients with asthma carry a type 2 inflammatory signature, and the sickest fifth of them account for the bulk of an $80 billion annual burden.

EP. 2: Severe Asthma Exacerbations, Indirect Costs, and When to Escalate Therapy

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 6th 2026

Asthma costs extend well beyond the emergency department, into lost schooling, reduced earning potential, and steroid harm, which sharpens the case for recognizing uncontrolled disease and escalating care promptly.

Advancing Asthma Management: Economic Burden, Unmet Needs, and the Evolving Role of IL-5 Inhibition

EP. 1: Type 2 Inflammation and the Economic Cost of Severe Asthma

EP. 2: Severe Asthma Exacerbations, Indirect Costs, and When to Escalate Therapy

Trending on AJMC

Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk

Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries

FDA Approves First Heart Valve to Keep Pace With Children's Growth

Psoriasis Is Much Rarer in Indigenous Groups Worldwide

Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending